Synonyms: BCX-4430 | BCX4430 | Immucillin-A
Compound class:
Synthetic organic
Comment: Galidesivir (BCX4430) is an adenosine analogue and broad-spectrum antiviral agent [3]. It was originally developed as a treatment for hepatitis C infection, but has subsequently demonstrated activity against Ebola, Marburg and Zika [1] viruses, and was most recently evaluated for potential to treat SARS-CoV-2 infection (COVID-19). Mechanistically it inhibits the virus' RNA-dependent RNA-polymerase (RdRp), that acts as a nonobligate RNA chain terminator.
|
|
References |
1. Bernatchez JA, Tran LT, Li J, Luan Y, Siqueira-Neto JL, Li R. (2020)
Drugs for the Treatment of Zika Virus Infection. J Med Chem, 63 (2): 470-489. [PMID:31549836] |
2. Choy KT, Wong AY, Kaewpreedee P, Sia SF, Chen D, Hui KPY, Chu DKW, Chan MCW, Cheung PP, Huang X et al.. (2020)
Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antiviral Res, 178: 104786. [PMID:32251767] |
3. Warren TK, Wells J, Panchal RG, Stuthman KS, Garza NL, Van Tongeren SA, Dong L, Retterer CJ, Eaton BP, Pegoraro G et al.. (2014)
Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature, 508 (7496): 402-5. [PMID:24590073] |